Literature DB >> 29430576

Prevalence and correlates of diabetes mellitus and dyslipidaemia in a long-stay inpatient schizophrenia population in Singapore.

Saleha Shafie1, Siau Pheng Lee1, Samantha Bee Cheng Ong2, Peizhi Wang1, Esmond Seow1, Hui Lin Ong1, Siow Ann Chong1, Mythily Subramaniam1.   

Abstract

INTRODUCTION: Patients with schizophrenia have shorter life expectancy and one of the main causes of death is cardiovascular disease (CVD). Modifiable risk factors for CVD include diabetes mellitus (DM) and dyslipidaemia. This study aimed to establish: (a) the prevalence and correlates of DM and dyslipidaemia; (b) the proportion of those whose condition was well controlled; and (c) the incidence of undiagnosed DM and dyslipidaemia in a long-stay inpatient schizophrenia population.
METHODS: Data was collected to assess the physical health status of 110 inpatients with schizophrenia who had been in hospital for over one year. Information on sociodemographic characteristics, diagnosis of physical and mental illnesses, and current medications was obtained from their medical records. The overall prevalence of DM and dyslipidaemia was based on diagnosis in the medical records, current medications and fasting blood test results.
RESULTS: The patient group was predominantly male (85.5%), with a mean age of 55.9 ± 9.9 (range 25-90) years. Overall prevalence of DM and dyslipidaemia was 19.1% and 62.7%, respectively. Multivariate logistic regression analysis showed that Malay (odds ratio [OR] 14.97) and Indian (OR 25.71) patients were significantly more likely to have DM when compared to Chinese patients.
CONCLUSION: In comparison to the general population, the prevalence of DM and dyslipidaemia was found to be higher in inpatients with schizophrenia. However, the two chronic illnesses were well controlled in inpatients and few were undiagnosed, perhaps due to the regular monitoring, supervised diet and regular physical activities arranged for inpatients in the long-stay inpatient wards. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  diabetes mellitus; dyslipidaemia; long-stay inpatients; schizophrenia

Mesh:

Substances:

Year:  2018        PMID: 29430576      PMCID: PMC6158135          DOI: 10.11622/smedj.2018020

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  41 in total

1.  Staying relevant with the times--the changing face of an asylum.

Authors:  Siow Ann Chong; Aditya Subramaniam
Journal:  Ann Acad Med Singap       Date:  2014-10       Impact factor: 2.473

Review 2.  Mortality in schizophrenia.

Authors:  Pascal Auquier; Christophe Lançon; Frédéric Rouillon; Malcolm Lader; Catriona Holmes
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-12       Impact factor: 2.890

3.  Body mass index in persons with schizophrenia.

Authors:  S Coodin
Journal:  Can J Psychiatry       Date:  2001-08       Impact factor: 4.356

4.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

5.  Excess mortality of schizophrenia. A meta-analysis.

Authors:  S Brown
Journal:  Br J Psychiatry       Date:  1997-12       Impact factor: 9.319

6.  Ethnic differences among Chinese, Malay and Indian patients with type 2 diabetes mellitus in Singapore.

Authors:  C Y Hong; K S Chia; K Hughes; S L Ling
Journal:  Singapore Med J       Date:  2004-04       Impact factor: 1.858

Review 7.  Obesity, serious mental illness and antipsychotic drugs.

Authors:  Richard I G Holt; Robert C Peveler
Journal:  Diabetes Obes Metab       Date:  2009-05-19       Impact factor: 6.577

8.  Body mass index, obesity, and psychopathology in patients with schizophrenia.

Authors:  Mythily Subramaniam; Max Lam; Meng En Guo; Vincent Y F He; Jimmy Lee; Swapna Verma; Siow Ann Chong
Journal:  J Clin Psychopharmacol       Date:  2014-02       Impact factor: 3.153

9.  Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis.

Authors:  Swapna Verma; Alvin Liew; Mythily Subramaniam; Lye Yin Poon
Journal:  Aust N Z J Psychiatry       Date:  2009-09       Impact factor: 5.744

10.  Relationship between SSRIs and Metabolic Syndrome Abnormalities in Patients with Generalized Anxiety Disorder: A Prospective Study.

Authors:  Murat Beyazyüz; Yakup Albayrak; Oğuzhan Bekir Eğilmez; Neslihan Albayrak; Elmas Beyazyüz
Journal:  Psychiatry Investig       Date:  2013-05-30       Impact factor: 2.505

View more
  4 in total

1.  Comment on: Prevalence and correlates of diabetes mellitus and dyslipidaemia in a long-stay inpatient schizophrenia population in Singapore.

Authors:  Mustafa Afifi
Journal:  Singapore Med J       Date:  2019-02       Impact factor: 1.858

2.  Authors' reply.

Authors:  Saleha Shafie; Siau Pheng Lee; Samantha Bee Cheng Ong; Peizhi Wang; Esmond Seow; Hui Lin Ong; Siow Ann Chong; Mythily Subramaniam
Journal:  Singapore Med J       Date:  2019-02       Impact factor: 1.858

3.  Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications.

Authors:  Nayyer Jaberi; Elnaz Faramarzi; Mostafa Farahbakhsh; Alireza Ostadarahimi; Mohammad Asghari Jafarabadi; Ali Fakhari
Journal:  Caspian J Intern Med       Date:  2020-05

4.  Prevalence and correlates of metabolic syndrome and its components in adults with psychotic disorders in Eldoret, Kenya.

Authors:  Edith Kwobah; Nastassja Koen; Ann Mwangi; Lukoye Atwoli; Dan J Stein
Journal:  PLoS One       Date:  2021-01-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.